Blog

About Bio pharmazeutika werden

The newest generation of biotechnological medicine that are usually derived from living cells, are changing the way that medical conditions are treated. As opposed to traditional small molecule medications that use chemicals, bio pharmazeutika are produced from a wide range of biological compounds and are intended to treat a variety of illnesses that have not been adequately addressed by conventional treatments made from small molecules.

Biopharmazeutika werden are produced using gentechnische production (GTP) from in cultured bacteria, mammalian cells such as the popular CHO-Zellen, or even plants, which can be cultivated using plant biotechnology (Pflanzenbiotechnologie). In contrast to traditional pharmaceuticals, which are produced in the lab using chemical methods and processes, all biopharmazeutika are created inside living organisms and have to be distinguished by their individual atom-by-atom structure.

Bio pharmazeutika can, due to their complexity and uniqueness, be difficult to be reproduced by chemical scientists. This is the reason they are classified as biosimilars, not simply generics. After the patent protection for an original medication expires companies can manufacture and market their own versions, provided they meet certain statutory requirements. They are known as Biosimilar Guidelines.

Biopharmazeutika may be administered directly or as an ingredient in the manufacture of a variety of therapeutic devices, including polysaccharides, peptides, and vaccines. These materials are recombined during the subsequent processing of Biopharmazeutika to produce complex biologic drugs. Recombinant biopharmazeutika comprises insulin, interleukin, and monoclonal antibodies.

www.genotec-frankfurt.de/bio-pharmazeutika-werden-zu-einer-anerkannten-form-der-alternativmedizin/